Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Withdrawn 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Sarcoma 1

Conditions

Multiple Myeloma 25Leukemia, Myeloid, Acute 24Lymphoma 22Breast Neoplasms 20Prostatic Neoplasms 15Colorectal Neoplasms 15Melanoma 14Leukemia, Lymphocytic, Chronic, B-Cell 14Lung Neoplasms 13Carcinoma, Non-Small-Cell Lung 13Neoplasm Metastasis 12Myelodysplastic Syndromes 12Lymphoma, Large B-Cell, Diffuse 12Squamous Cell Carcinoma of Head and Neck 11Pancreatic Neoplasms 11Ovarian Neoplasms 10Myeloproliferative Disorders 10Triple Negative Breast Neoplasms 8Rectal Neoplasms 8Leukemia, Myelomonocytic, Chronic 8Carcinoma, Renal Cell 8Burkitt Lymphoma 8Sarcoma 7Lymphoma, Follicular 7Colonic Neoplasms 7Urinary Bladder Neoplasms 6Lymphoma, Non-Hodgkin 6Glioma 6Fallopian Tube Neoplasms 6Cholangiocarcinoma 6

Interventions

Trabectedin 3Radiation Dose Hypofractionation 3Cyclophosphamide 3fludarabine 2ribociclib 1pembrolizumab 1interferon gamma-1b 1cytochrome C synthetase 1brostallicin 1atezolizumab 1Sirolimus 1Pioglitazone 1Interferon-gamma 1Diathermy 1Dexamethasone 1Biopsy 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 2 × Liposarcoma, Myxoid × Biopsy × Clear all
NCT03397186 2019-09-10

Immune Changes Following Trabectedin in Patients With Metastatic or Unresectable Sarcoma

Fred Hutchinson Cancer Center

Phase 2 Withdrawn
Sarcoma

Sarcoma, Liposarcoma, Myxoid

Data powered by HemOnc (CC BY 4.0) Colophon âš¡